Sept 13 (Reuters) - Japan's Takeda Pharmaceuticalis considering selling Shire Plc's eye care businessonce it closes its $62 billion purchase of the London-listeddrugmaker, as it looks to cut the debt raised to fund the deal,Bloomberg reported on Thursday.
Takeda is weighing the sale of Shire's Xiidra drug whichtreats dry eye, as well as its Natpara medicine used to controllow blood calcium levels, the report said https://www.bloomberg.com/news/articles/2018-09-13/takeda-is-said-to-weigh-sale-of-shire-eye-care-drug-to-cut-debt,citing people familiar with the matter.
The sale could help Takeda raise between $4 billion and $5billion, Bloomberg reported.
Takeda agreed to buy Shire in May, in what would be thelargest overseas purchase by a Japanese company.
Neither Takeda nor Shire immediately responded to Reuters'requests for comment.(Reporting by Sai Sachin Ravikumar)